Progenics Pharmaceuticals Inc
PGNX
PGNX was delisted on the 19th of June, 2020.
126 hedge funds and large institutions have $518M invested in Progenics Pharmaceuticals Inc in 2016 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 36 increasing their positions, 44 reducing their positions, and 17 closing their positions.
109% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $1.05M
82% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 17
36% more capital invested
Capital invested by funds: $382M → $518M (+$136M)
10% more funds holding
Funds holding: 115 → 126 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$19.7M |
| 2 |
PWAM
Park West Asset Management
San Francisco,
California
|
+$5.1M |
| 3 |
GAM
Gotham Asset Management
New York
|
+$3.55M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$2.92M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$2.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$15.4M |
| 2 |
Goldman Sachs
New York
|
-$4.95M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.76M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$3.7M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.25M |
PGNX Hedge Fund Activity: Q4 2016 in Review
126 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2016, worth a combined $518M — up 36% from $382M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new PGNX positions and 17 closed out — a net gain of 14 holders — while 36 added to existing stakes and 44 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $19.7M. The largest seller was Millennium Management, cutting an estimated $15.4M.
- 126 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2016, up from 115 in Q3 2016.
- Funds reported $518M of Progenics Pharmaceuticals Inc stock for Q4 2016, up 36% quarter-over-quarter.
- 31 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2016 and 17 closed out, a net change of +14 holders.
- The largest Progenics Pharmaceuticals Inc buyer in Q4 2016 was Eagle Asset Management, an estimated $19.7M added.
- The largest Progenics Pharmaceuticals Inc seller in Q4 2016 was Millennium Management, an estimated $15.4M sold.
Based on aggregated 13F filings for Q4 2016.